UPCOMING KMR WEBINARS
Wednesday,
Feb 19
10:30 am EST

Sponsors Only

Measuring the performance of clinical trial trials requires a solid framework of how and what to measure grounded by standard definitions and an unbiased third party to ensure data integrity. The data is just the beginning, KMR Group creates benchmarks and advanced analytics that drive insight from specific pain points to statistically validated drivers of duration. Companies participating in the program benefit from access to reports, tools, members only webinars, user meetings and options for a la carte or project specific consulting opportunities that are all grounded by our peerless data sources. Find out more about why the most innovative companies in the industry rely on KMR to help them drive performance improvements by over 30% using the most reliable and trusted dataset in the industry. Free
Tuesday,
Mar 17
10:30 am EST

Sponsors Only

Oncology performance in R&D is one of the more complex with evolving and changing drug development paradigms. Understanding how long it takes to bring a new Oncology drug to market and at what cost needs to be considered in light of skipping phases, parallel development, combinations, sharing and more . The session also addresses success rates, value and productivity from the Oncology perspective. Find out more about measuring R&D Oncology and how these principles can be applied to help your organization measure the performance of Oncology R&D and at the same time learn more about our R&D Oncology Performance Study. Free
Wednesday,
Sep 2
10:30 am EST

Sponsors Only

Measuring R&D Productivity goes beyond simply counting NME approvals and dividing by spending although that is a valid and key way to assess performance. In addition to basic productivity metrics, we present a variety of both leading and lagging productivity indicators to assess both output and value of R&D performance. Free
TBD

Sponsors Only

The live webinars provides a framework for measuring the performance of discovery research using both target and NME analytics and relying on both operational performance and outcomes based metrics. The metrics go beyond simply measuring how many assets get into development and focus on whether the objectives or hypotheses of discovery are successful. This means looking at both leading and lagging indicators to assess both how long and how many shots on goal it took to get a successful NME into the market. Free
TBD A case study which illustrates the power of how applying precision analytics in upfront design and operational choices can reduce cycle times. A paper will be provided to attendees. $250
TBD

Members Only

Highlights from KMR 2019 Cycle Time Report covering benchmarks, trends and developments across the industry. Find out which processes are getting longer from study startup to reporting and which factors from study design to operational performance are statistically significant in driving durations. Questions of interest and input for next year’s study with respect to new metrics and analysis are requested to be submitted in advance. We apologize but this session only available to current members of KMR Group clinical program. Free
TBD Calculating and interpreting success rates is extremely complex and requires a deep understanding of drug development and risk. This session outlines some of the essentials that go into a robust assessment of success based on our long history measuring, evaluating and developing more nuanced risk based performance models. The session identifies a variety of ways to measure success rates and how various aspects of performance including licensing and acquisition along with divestiture can bias results. Companies that want an unbiased and unvarnished assessment of their performance come to KMR as their trusted data source and analytics partner. Free